| 129 | 0 | 18 |
| 下载次数 | 被引频次 | 阅读次数 |
肝硬化腹水属于中医“鼓胀”范畴，为中医四大难症之一。李红霞主任结合各代医家思想及前人理论和实践经验，认为鼓胀的病机是肝、脾、肾、肺受损，气滞、血瘀、水停、食积于腹中，治疗老年乙肝肝硬化腹水，温阳为治病之本，顾脾、提壶揭盖是关键，还须标本同治，总结温阳消鼓方临床运用疗效显著，并附医案加以佐证，为中医治疗老年乙肝肝硬化腹水提供思路。
Abstract：Ascites in cirrhosis falls under the category of tympanites in traditional Chinese medicine(TCM) and is one of the four major difficult conditions in TCM.Director Li Hongxia,drawing on the ideas of medical experts from various generations and the theoretical and practical experience of her predecessors,believes that the pathogenesis of tympanites involves damage to the liver,spleen,kidney,and lung,which leads to qi stagnation,blood stasis,fluid retention,and food accumulation in the abdomen.In treating hepatitis B-related cirrhotic ascites in elderly patients,warming yang is the fundamental principle,while protecting the spleen and "lifting the lid of the teapot" are the key points.Additionally,both the root and branch of the condition must be addressed simultaneously.This article summarizes the clinical efficacy of Wenyang Xiaogu Formula,with case studies provided as evidence,offering an approach for TCM treatment of hepatitis B-related cirrhotic ascites in elderly patients.
[1]单姗，赵连晖，马红，等.肝硬化的定义、病因及流行病学[J].临床肝胆病杂志，2021,37(1):14-16.
[2]XU X, DUAN Z, DING H, et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J]. Hepatology International, 2019, 13(1):1-21.
[3]PLANAS R, MONTOLIU S, BALLESTE B, et al.Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clinical Gastroenterology and Hepatology, 2006, 4(11):1385-1394.
[4]BIECKER E. Diagnosis and therapy of ascites in liver cirrhosis[J]. World Journal of Gastroenterology:WJG, 2011, 17(10):1237-1248.
[5]CALY W R, ABREU R M, BITELMAN B, et al.Clinical features of refractory ascites in outpatients[J]. Clinics, 2017, 72(7):405-410.
[6]周翔天，夏粤华，李旭，等.三种不同技术治疗老年顽固性肝硬化腹水效果对比[J].中国老年学杂志，2022,42(7):1626-1629.
[7]徐小元，丁惠国，李文刚，等.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志，2017,33(10):1847-1863.
[8]LV Y, WANG Q, LUO B, et al. Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding[J]. Journal of Hepatology, 2025, 82(2):245-257.
[9]LIU J, MA J, YANG C, et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement[J]. Radiology,2022, 303(3):711-719.
[10]SCHINDLER P, HEINZOW H, TREBICKA J, et al. Shunt-induced hepatic encephalopathy in TIPS:current approaches and clinical challenges[J]. Journal of Clinical Medicine,2020, 9(11):3784.
[11]王晓静，冯颖，刘尧，等.肝硬化腹水中医诊疗专家共识（2023）[J].临床肝胆病杂志，2023,39(12):2775-2781.
[12]李爱勇.黄帝内经[M].北京：民主与建设出版社，2021.
[13]李佑桥，郑其进.益气温阳法治疗肝硬化腹水的临床研究[J].中医学报，2011,26(8):976-977.
[14]杨莉，王晓光.温阳益气汤联合恩替卡韦治疗老年失代偿期乙肝后肝硬化患者的疗效研究[J].中国现代药物应用，2018,12(13):121-123.
[15]达君.难经问难[M].广州：广东科学技术出版社，2025:224.
[16]李杲，别玉龙.兰室秘藏[M].北京：中国中医药出版社，2019.
[17]张仲景.金匮要略[M].赵立凝，整理.广州：广东科学技术出版社，2022.
[18]奥敦托娅，赵海珍，刘瑞军，等.中药脐贴联合苓桂术甘汤化载内服辨治脾肾阳虚证肝硬化腹水的临床效果[J].世界中医药，2016,11(10):2050-2053.
[19]田莉婷，刘雪萍，李丹妮，等.加味苓桂术甘汤对脾肾阳虚型肝硬化失代偿期患者生存率的影响[J].陕西中医，2019,40(10):1373-1376.
[20]王振常，黄晶晶，宾容，等.从肺论治肝硬化腹水[J].辽宁中医药大学学报，2013,15(1):17-18.
[21]杨新莉，黄冰冰，卢秉久，等.三消汤治疗肝硬化腹水的临床方案研究[J].辽宁中医杂志，2013,40(10):1997-2001.
[22]王宁，吕文良.从三焦理论辨治肝硬化腹水[J].辽宁中医杂志，2023,50(10):66-68.
[23]李用粹，吴唯.证治汇补[M].北京：中国中医药出版社，1999.
[24]尹笑玉，陈明.试论“提壶揭盖”法及其扩展应用[J].辽宁中医杂志，2023,50(9):60-64.
[25]杨楚琪，崔言坤，吴含章，等.从开阖枢论提壶揭盖法之调畅气机[J].中华中医药杂志，2022,37(5):2436-2439.
[26]李世云，李道宽.麻黄汤加减联合西药治疗肝硬化腹水30例[J].上海中医药杂志，2008(11):39-40.
[27]万洁，陈潇颖，于君，等.国医大师周仲瑛三焦四道论辨治肝硬化腹水[J].中华中医药杂志，2025,40(4):1723-1726.
[28]许欣，李刚敏，孙晨，等.附子水溶性生物碱及其药理作用研究进展[J].中药药理与临床，2021,37(5):213-219.
[29]史攀博，李亨达，薛宁，等.附子药理、毒理及解毒机制研究述评[J].中医学报，2023,38(11):2347-2353.
[30]KUCUKLER S , DARENDELIOGLU E ,CAGLAYAN C, et al. Zingerone attenuates vancomycin-induced hepatotoxicity in rats through regulation of oxidative stress, inflammation and apoptosis[J]. Life Sciences, 2020, 259(15):118382.
[31]田婷，陈华，殷璐，等.茯苓和茯苓皮水和乙醇提取物的利尿作用及其活性成分的分离鉴定[J].中国药理学与毒理学杂志，2014,28(1):57-62.
[32]段会平，侯安继，陆付耳，等.羧甲基茯苓多糖对HBV转染细胞表达功能影响的实验研究[J].中华实验和临床病毒学杂志，2005,19(3):290-292.
[33]胡永红，任爽，刘伟，等.黄芪总苷上调miRNA-744表达抑制肝星状细胞活化的效应机制[J].上海中医药大学学报，2021,35(1):32-40.
[34]符秋雨，王飞虾，张峰，等.白术内酯Ⅲ调控ASCT2介导的线粒体-溶酶体互作诱导肝星状细胞衰老的抗肝纤维化机制研究[J].南京中医药大学学报，2024,40(4):341-349.
[35]蒋飞，秦依雯.粉防己碱上调PTEN表达逆转肝细胞癌细胞顺铂耐药的研究[J].中国临床药理学杂志，2024,40(11):1565-1568.
[36]ZHANG X, LI X Y, LIN N, et al. Diuretic activity of compatible triterpene components of Alismatis rhizoma[J]. Molecules, 2017, 22(9):1459.
[37]刘云鹤，蔡金保，王红丽，等.党参多糖抑制PI3K/AKT通路对人肝癌HepG2细胞生长和运动能力的影响[J].中国免疫学杂志，2020,36(9):1108-1113.
[38]MIAO S M, ZHANG Q, BI X B, et al. A review of the phytochemistry and pharmacological activities of Ephedra herb[J]. Chinese Journal of Natural Medicines, 2020, 18(5):321-344.
基本信息:
DOI：10.20065/j.cnki.btcm.20260045
中图分类号:R249;R259
引用信息:
[1]王瑶瑶,李红霞.李红霞治疗老年乙肝肝硬化腹水的经验[J].基层中医药,2026,5(02):36-42.DOI:10.20065/j.cnki.btcm.20260045.
2025-08-21
2025
2025-11-10
2025
1
2026-02-12
2026-02-12
2026-02-12